Anti-VEGF Cancer Therapy in Nephrology Practice
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established....
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2014/143426 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564432034594816 |
|---|---|
| author | Hassan Izzedine |
| author_facet | Hassan Izzedine |
| author_sort | Hassan Izzedine |
| collection | DOAJ |
| description | Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity? |
| format | Article |
| id | doaj-art-c7474e8e5d9d40edb08391c7a4a388c0 |
| institution | Kabale University |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-c7474e8e5d9d40edb08391c7a4a388c02025-02-03T01:11:01ZengWileyInternational Journal of Nephrology2090-214X2090-21582014-01-01201410.1155/2014/143426143426Anti-VEGF Cancer Therapy in Nephrology PracticeHassan Izzedine0Department of Nephrology, Pitie-Salpetriere Hospital, 75013 Paris, FranceExpanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?http://dx.doi.org/10.1155/2014/143426 |
| spellingShingle | Hassan Izzedine Anti-VEGF Cancer Therapy in Nephrology Practice International Journal of Nephrology |
| title | Anti-VEGF Cancer Therapy in Nephrology Practice |
| title_full | Anti-VEGF Cancer Therapy in Nephrology Practice |
| title_fullStr | Anti-VEGF Cancer Therapy in Nephrology Practice |
| title_full_unstemmed | Anti-VEGF Cancer Therapy in Nephrology Practice |
| title_short | Anti-VEGF Cancer Therapy in Nephrology Practice |
| title_sort | anti vegf cancer therapy in nephrology practice |
| url | http://dx.doi.org/10.1155/2014/143426 |
| work_keys_str_mv | AT hassanizzedine antivegfcancertherapyinnephrologypractice |